AbbVie Inc. (0QCV.L)
| Previous close | 147.37 |
| Open | 150.11 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 146.93 - 147.40 |
| 52-week range | 146.93 - 147.40 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 2.191B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
NORTH CHICAGO, Ill. & EXTON, Pa., January 06, 2023--AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
- Globe Newswire
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseasesSosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2
- Business Wire
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark, July 18, 2022--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in the second half of 2022. Genmab recently announced that the company will submit a biologics license a
